Beyond one gene, one target: Next-generation precision oncology.

IF 21.6 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2026-07-01 Epub Date: 2026-06-20 DOI:10.1016/j.trecan.2026.06.006

Vivek Subbiah, Razelle Kurzrock

引用次数: 0

Abstract

The Drug Rediscovery Protocol by K. Verkerk, et al., operationalized nationwide biomarker-guided, off-label precision oncology. Yet outcomes (15.7% response rate) mirror a decade of studies, indicating a single biomarker-drug strategy ceiling. Advancing efficacy will require customized, individualized combinations, consistent with the hallmarks of cancer complexity and the I-PREDICT (Investigation of profile-related evidence determining individualized cancer therapy) style clinical studies framework, which shows that outcomes scale with greater biomarker matching.

查看原文本刊更多论文

超越一个基因，一个目标：下一代精确肿瘤学。

由K. Verkerk等人制定的药物再发现方案在全国范围内实施了生物标志物引导的非标签精确肿瘤学。然而，结果（15.7%的有效率）反映了十年来的研究，表明单一生物标志物-药物策略的上限。提高疗效需要定制、个性化的组合，与癌症复杂性的特征和I-PREDICT（确定个体化癌症治疗的相关证据调查）风格的临床研究框架相一致，这表明结果规模与更大的生物标志物匹配。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.